What development phase is 0.3% benzydamine hydrochloride spray oromucosal solution in?

0.3% benzydamine hydrochloride spray oromucosal solution is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

0.3% benzydamine hydrochloride spray oromucosal solution

Aziende Chimiche Riunite Angelini Francesco S.p.A · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	0.3% benzydamine hydrochloride spray oromucosal solution
Sponsor	Aziende Chimiche Riunite Angelini Francesco S.p.A
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Benzydamine in Sore Throat Pain Relief (BePaiR Study) (PHASE4)
Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

0.3% benzydamine hydrochloride spray oromucosal solution CI brief — competitive landscape report
0.3% benzydamine hydrochloride spray oromucosal solution updates RSS · CI watch RSS
Aziende Chimiche Riunite Angelini Francesco S.p.A portfolio CI